{"filing":{"accession_number":"0001654954-26-008359","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"a6888u.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426008359/a6888u.htm"},"events":[{"id":33420,"run_id":30728,"accession_number":"0001654954-26-008359","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"GSK announced entry into an agreement to acquire a trispecific T cell-engager programme from Chimagen Biosciences with a total potential value of up to $750 million. The disclosure explicitly describes the acquisition of full global rights to the asset, with upfront and milestone-based payments. This constitutes a material acquisition of an asset/programme, fitting the ma_activity category (Item 1.01 equivalent for 6-K filings).","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-15","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36867,"accession_number":"0001654954-26-008359","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"GSK announced entry into an agreement to acquire a trispecific T cell-engager programme from Chimagen Biosciences with a total potential value of up to $750 million. The disclosure explicitly describes the acquisition of full global rights to the asset, with upfront and milestone-based payments. This constitutes a material acquisition of an asset/programme, fitting the ma_activity category (Item 1.01 equivalent for 6-K filings).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-15T10:09:41.638564+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-09-15"}]}